


**BAUSCH + LOMB**

# enVista Envy™

Full Range of  
Vision IOLs



enVista ENVY™

**FLOURISH**  
**AT EVERY STEP**



Discover the **FULL RANGE OF VISION IOL** that launches  
a new era of confidence with enviable outcomes<sup>1</sup>



## FULL RANGE OF VISION CORRECTION

ACCESSIBLE TO ALL CATARACT SURGEONS<sup>1</sup>


## OUTSTANDING PERFORMANCE IN ALL LIGHTING CONDITIONS

WITH ACTIVSYNC - INTELLIGENT  
ENERGY DISTRIBUTION<sup>4</sup>

## TREAT MORE ASTIGMATIC PATIENTS WITH MORE PRECISION<sup>5</sup>

## EXCELLENT PATIENT TOLERANCE

TO GLARE, HALOS, AND STARBURSTS<sup>2,3</sup>



**A full range of  
vision comes with  
high expectations**

enVista  
HYDROPHOBIC ACRYLIC COAT  
ENVY™

# A lens with an enviable tolerance to dysphotopsia<sup>1, 2, 3\*</sup>

Types of dysphotopsia	enVista Envy <sup>1,2*</sup>			
	% of patients with little to no bothersomeness		% of patients with severe disturbance	
	US (n=309)	Canada (n=110)	US (n=309)	Canada (n=110)
Glare	88%	96%	3%	0%
Halos	80%	88%	6%	6%
Starbursts	91%	94%	3%	1%

Type of dysphotopsia	PanOptix (n=127) <sup>3*</sup>	
	% of patients with little to no bothersomeness	% of patients with severe disturbance
Glare	73%	3%
Halos	73%	13%
Starbursts	72%	16%


\*Respective patient reported outcome data at 4–6 months post-op (non-head-to-head) from enVista Envy US clinical study (n=309), 4–6 months post-op enVista Envy Canadian clinical study (n=110) and 6-month post-op AcrySof PanOptix clinical study (n=127)

# enVista Envy can enhance your patients' visual experience in their daily-life activities<sup>2</sup>



**91%**

**LITTLE TO NO DIFFICULTY  
READING MOBILE SCREEN<sup>2</sup>**



**94%**

**LITTLE TO NO DIFFICULTY  
VIEWING CLOSE OBJECTS<sup>2</sup>**



**95%**

**LITTLE TO NO DIFFICULTY  
READING COMPUTER SCREEN<sup>2</sup>**

**enVista**  
HYDROPHOBIC ACRYLIC IOL  
**ENVY™**

Canadian Clinical Study, enVista Envy n=110 patient reported outcomes 4-6-month post-op, bilateral implantation


**93%**  
of patients were  
completely to  
moderately  
satisfied with  
their vision<sup>2</sup>



enVista Envy Canadian Clinical Study, n=110 patient reported  
outcomes 4–6-month post-op, bilateral implantation

**ActivSync**  
optic delivers  
intelligent  
energy  
distribution


enVista  
HYDROPHOBIC ACRYLIC IOL ENVY™





The ActiveSync optic in enVista Envy is designed to **enhance image contrast** when patients need it most, evenly distributing light in photopic conditions and prioritizing distance in mesopic conditions.

**enVista Envy energy distribution according to pupil size<sup>4</sup>**




Based on bench testing

# enVista Envy demonstrated excellent performance


In **photopic conditions**, ActivSync optic maintained excellent full range of vision for patients.<sup>1,4</sup>

enVista Envy defocus curve 3-4mm pupil size<sup>1</sup>



# ...in all lighting conditions

In pupils larger than 4mm, ActivSync optic is able to prioritize light energy, which facilitates night vision.<sup>1,4</sup>



enVista Envy US Clinical Study, binocular implantation, 4-6-month post-op, n=36 eyes

## Intelligent optic design meets exceptional engineering

- Full range of vision diffractive anterior surface
- 1.2mm central zone
- 1.6 D intermediate and 3.1 D near adds
- Consistent  $-0.15\mu\text{m}$  SA profile across full diopter range




12.5mm  
lens length

6mm optic  
diameter

SA = spherical aberration

enVista  
HYDROPHOBIC ACRYLIC LENS  
ENVY™

In addition to **ActivSync optic**, enVista Envy is enhanced with **proprietary technology** designed to reduce light scattering.<sup>4</sup>



Data on file. enVista Envy.



**enVista Envy  
demonstrated  
exceptional  
visual outcomes<sup>1</sup>**

**enVista**  
HYDROPHOBIC ACRYLIC OIL  
**ENVY**

enVista Envy US Clinical Study

# enVista Envy performance is supported by a robust US clinical study

A multicenter, randomized, and controlled clinical trial which assessed the safety and effectiveness of the enVista Envy IOL included a one-year follow-up period and demonstrated excellent long-term outcomes.<sup>1</sup>



**332** ENVISTA ENVY  
(TEST GROUP)

**169** ENVISTA  
(CONTROL GROUP)

**23** INVESTIGATION  
SITES

664 number of eyes


338 number of eyes

enVista Envy US Clinical Study

**enVista Envy™ delivers  
excellent image contrast  
for low-light visual clarity<sup>4</sup>**

enVista  
HYDROPHOBIC ACRYLIC IOL  
ENVY™

# Help your patients achieve spectacle independence<sup>1</sup>



\*enVista Envy US Clinical Study, n=53 patients reported outcomes 4-6-month post-op, bilateral

# enVista Envy achieved excellent mean visual acuity results in a robust US clinical study<sup>1</sup>

Near



DCNVA Bilateral  
Photopic Conditions  
n=284

Intermediate



DCIVA Bilateral  
Photopic Conditions  
n=283

Distance



BCDVA Bilateral  
Photopic Conditions  
n=312

enVista  
HYDROPHOBIC ACRYLIC IOL  
ENVY™


enVista Envy US Clinical Study, bilateral implantation, 4–6-month post-op



# enVista ENVY™ TORIC

## Spectacle independence is achievable

Studies have shown that patients who received a full range of vision IOL lens with  $>0.5$  D of residual astigmatism see a significant reduction in their quality of distance vision.<sup>6,7,9</sup>



Correcting cataracts  
and astigmatism.

**BOTH at the same time.**

### **Benefits of Toric IOLs**

- Reduces the need for additional refractive correction procedures.
- Provides greater accuracy and range than corneal-incisional and limbal-relaxing procedures.<sup>8</sup>


# Low-Cyl technology expands premium options for low astigmatism treatment

## With Low-Cyl technology:

Broaden the treatable astigmatism range in cataract surgery to as low as  $<1.0$  D at the corneal plane.<sup>10</sup>

## The first and only full range of vision toric platform available in the US


providing Low-Cyl toric technology (1.25 D at the IOL plane)



of cataract patients have less than 1.25 D of corneal astigmatism.<sup>11</sup>

# Astigmatism treatment options for MORE patients with MORE precision<sup>5</sup>


- **Lowest** available cylinder treatment: 1.25 D at IOL plane (<1 D at corneal plane)\*
- **Highest** available cylinder treatment: 5.75 D at IOL plane\*
- **Only** toric platform that treats half-step cylinders (up to 3.5 D at IOL plane)\*



\*Comparison to available multifocal toric platforms approved in the US


# The enVista platform is tailored for EXCELLENT stability and toric outcomes

Toric alignment and rotational stability are vital for patient satisfaction and visual outcomes.




**1° Lens Rotation**

Effectiveness 96.7%<sup>15</sup>




**5° Lens Rotation**

Effectiveness 83.5%<sup>15</sup>



**10° Lens Rotation**


Effectiveness 67%<sup>15</sup>



**30° Lens Rotation**


Effectiveness 1%<sup>15</sup>

**110°** of capsular bag contact



enVista toric platform<sup>4</sup>

**88°** of capsular bag contact



AcrySof IQ/CLAREON<sup>4</sup>  
toric platform

**84°** of capsular bag contact





TECNIS toric platform<sup>4</sup>

## Achieve reliable rotational stability for precise astigmatism correction

- 110° of capsular bag contact
- Delivers 300% more radial compression force than traditional hydrophobic IOLs<sup>16</sup>
- Demonstrated higher outward radial force compared to the TECNIS IOL toric platform<sup>16</sup>

**Radial compression force - IOL platforms<sup>17</sup>**





The enVista toric platform delivers proven rotational stability through **180 days post-surgery**<sup>4</sup>

Percent of eyes  $\leq 5^\circ$  rotation ( $n=108$ )


enVista  
HYDROPHOBIC ACRYLIC IOL  
ENVY TORIC

enVista Toric MX60ET US Clinical Study

# Simplified intraoperative lens manipulation

The unique fenestration holes of enVista Envy Toric simplify lens manipulation during surgery,<sup>26</sup> allowing **both clockwise and counterclockwise** positioning in the capsular bag.

The fenestrated haptics also reduce haptic-to-optic stress, ensuring lens integrity during capsular bag contraction.



# The enVista Toric Calculator

## Your partner in accuracy

Powered by the advanced Emmetropia Verifying Optical (EVO) formula, the enVista Toric Calculator sets the new standard for predicting spherical equivalence and providing data for low astigmatism cases.<sup>18</sup>

The EVO formula includes posterior corneal astigmatism (PCA) modeling and IOL geometry considerations<sup>1</sup> to determine spherical equivalent refractive error, and the suitable IOL power, based on biometry.

### Using the EVO formula:

- Around 80% of patients achieve a targeted range of 0 to 0.5 D, surpassing traditional vergence formulas.<sup>19</sup>
- The proportion of eyes with a refractive astigmatism of  $\leq 1.0$  D is statistically superior compared to the Kane formula.<sup>25</sup>
- Improved alignment between predicted and actual refractive astigmatism compared to legacy formulas.<sup>18</sup>



Scan to access the enVista Toric Calculator  
<https://envista.toriccalculator.com/>

## Delivery systems

Available for enVista Envy and enVista Envy Toric IOLs



### **BLIS®** (reusable solution)

- Quality engineering and built from high-grade titanium
- Requires a small incision size of 2.2mm to 2.4mm, for smooth lens deliveries<sup>20</sup>



### **INJ100** (single-use solution)


- Uses a silicone soft-tip to deliver consistent lens folding – reproducible and reliable delivery into the capsular bag<sup>21</sup>
- Requires a small incision size of 2.2mm to 2.6mm, for smooth lens deliveries<sup>21</sup>

# enVista

HYDROPHOBIC ACRYLIC IOL

## ENVY™

EN order number ENUXXXX



X represents diopter

MODEL NUMBER	EN (non-preload)
MATERIAL	Hydrophobic Acrylic
OPTIC DESIGN	One-piece Aspheric, biconvex Anterior apodized diffractive Posterior refractive Posterior aspheric surface 1.6 D intermediate 3.1 D near
OPTIC SIZE	6mm
LENGTH	12.5mm
OPTIC EDGE DESIGN	Sharp 360° square posterior edge
HAPTICS	Modified C, fenestrated
REFRACTIVE INDEX	1.53 at 35° C
UV CUTOFF	389nm at 10% transmittance
OPTICAL BIOMETRY	
Optical A-constant*	119.5
ACD	5.84mm
Surgeon Factor	2.06mm
APPLANATION BIOMETRY	
Applanation A-constant*	119.2
ACD	5.60mm
Surgeon Factor	1.89mm
OTHER FEATURES	Glistering free
DIOPTRER RANGE	+6 D to +10 D (1.0 D increments) +10 D to +34 D (0.5 D increments)


\* A-constant values are suggested as a guideline. Physicians should calculate lens power based on optimization of their experience and preference with IOL technology.

# enVista TORIC

HYDROPHOBIC ACRYLIC IOL

ENVY™

ETN order number ETNU CCC+XXX



C represents cylinder, X represents diopter

MODEL NUMBER	ETN (non-preload)
MATERIAL	Hydrophobic Acrylic
OPTIC DESIGN	One-piece Aspheric, biconvex Anterior apodized diffractive Posterior refractive Posterior toricity 1.6 D intermediate 3.1 D near
OPTIC SIZE	6mm
LENGTH	12.5mm
OPTIC EDGE DESIGN	Sharp 360° square posterior edge
HAPTICS	Modified C, fenestrated
REFRACTIVE INDEX	1.53 at 35° C
UV CUTOFF	389nm at 10% transmittance
OPTICAL BIOMETRY	
Optical A-constant*	119.5
ACD	5.84mm
Surgeon Factor	2.06mm
APPLANATION BIOMETRY	
Applanation A-constant*	119.2
ACD	5.60mm
Surgeon Factor	1.89mm
OTHER FEATURES	Glistering free
DIOPTER RANGE	+6 D to +34 D (0.5 D increments)
CYLINDER POWERS IOL PLANE	1.25, 1.50, 2.00, 2.50, 3.00, 3.50, 4.25, 5.00, 5.75 D

\* A-constant values are suggested as a guideline. Physicians should calculate lens power based on optimization of their experience and preference with IOL technology.

## Indications and Important Safety Information for enVista Envy™ IOL

**INDICATIONS:** The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

**WARNINGS/PRECAUTIONS:** Physicians should weigh the potential risk/benefit ratio before implanting the enVista Envy lens under any of the circumstances or conditions outlined in the Instructions for Use labeling. Some visual disturbances may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or radial lines around point sources of light (starbursts) under nighttime conditions, glare, double vision, haziness and blurred vision. It is expected that, in a small percentage of patients, the observation of such phenomena will be annoying and may be perceived as a hindrance, particularly in low illumination conditions such as nighttime driving. As with other trifocal IOLs, there is a possibility that visual disturbances may be significant enough that the patient will request explant of the IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients, therefore, patients implanted with trifocal IOLs should exercise caution when driving at night or in low light or poor visibility conditions. Care should be taken to achieve IOL centration as IOL decentration may result in patients experiencing visual disturbances or suboptimal vision under certain lighting conditions. The surgeon must target emmetropia to achieve optimal visual performance. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Please provide a copy of the Patient Information Brochure, which can be found at [www.bausch.com/IFU](http://www.bausch.com/IFU). Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs earlier in its progression than patients with monofocal IOLs. This may be due to the reduced contrast sensitivity observed with multifocal IOLs.

**CAUTION:** Federal law restricts this device to sale by or on the order of a physician.

**ATTENTION:** See the Directions for Use for a complete listing of indications and important safety information.

## Indications and Important Safety Information for enVista Envy™ Toric IOL

**INDICATIONS:** The enVista Envy toric hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

**WARNINGS/PRECAUTIONS:** Physicians should weigh the potential risk/benefit ratio before implanting the enVista Envy lens under any of the circumstances or conditions outlined in the Instructions for Use labeling. Some visual disturbances may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or radial lines around point sources of light (starbursts) under nighttime conditions, glare, double vision, haziness and blurred vision. It is expected that, in a small percentage of patients, the observation of such phenomena will be annoying and may be perceived as a hindrance, particularly in low illumination conditions such as nighttime driving. As with other trifocal IOLs, there is a possibility that visual disturbances may be significant enough that the patient will request explant of the IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients, therefore, patients implanted with trifocal IOLs should exercise caution when driving at night or in low light or poor visibility conditions. Care should be taken to achieve IOL centration as IOL decentration may result in patients experiencing visual disturbances or suboptimal vision under certain lighting conditions. The surgeon must target emmetropia to achieve optimal visual performance. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Please provide a copy of the Patient Information Brochure, which can be found at [www.bausch.com/IFU](http://www.bausch.com/IFU). Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs earlier in its progression than patients with monofocal IOLs. This may be due to the reduced contrast sensitivity observed with multifocal IOLs. The enVista Envy Toric IOL has not been evaluated in a clinical study. In general, astigmatism that is corrected with a higher cylinder power IOL can result in clinically significant residual astigmatism. The effect of residual astigmatism at distance, intermediate, and near was evaluated in a clinical study of patients who had been implanted with non-toric enVista Envy IOLs and were induced with cylinder power to simulate various levels of residual astigmatism. If a secondary surgical intervention is necessary to reposition the IOL, explantation should be considered as some patients may have recurrent or persistent issues related to rotational instability and misalignment.

**CAUTION:** Federal law restricts this device to sale by or on the order of a physician.

**ATTENTION:** See the Directions for Use for a complete listing of indications and important safety information.

# Advanced enVista IOL platform features

## TruSight® technology

Glistening-free material\* with improved scratch resistance and 25x the hardness of traditional hydrophobic acrylic IOLs.<sup>22,\*\*</sup>

## StableFlex® technology

Efficient lens unfolding, ensuring excellent optic recovery.<sup>12</sup>

## SureEdge® design

Outstanding defense against Posterior Capsular Opacification (PCO).<sup>12,24</sup>



\*Glistenings are observed by ophthalmologists at the slit lamp as backscatter. There has been no established correlation between these backscatter observations and what patients observe.

\*\*Based on nanoindentation study

## References

1. Data on File. enVista Envy US Clinical Study.
2. Data on File. enVista Envy Canadian Clinical Study.
3. Alcon AcrySof PanOptix Clinical Study.
4. Data on File, Bausch+Lomb.
5. enVista Envy Toric Directions for Use, Bausch & Lomb.
6. Hayashi K, Yoshida M, Igarashi C, Hirata A. Effect of Refractive Astigmatism on All-Distance Acuity in Eyes with a Trifocal Intraocular Lens. *American J Ophthalmol.* 2021;221: 279-286. doi: 10.1016/j.ajo.2020.07.051.
7. Zhang L, Shen W, Shen J, Wang M, Ni S, Guo H, Yang J. Effect of Postoperative Residual Astigmatism on Visual Outcomes After Trifocal Intraocular Lens Implantation. *Front Med.* 2023; 10:1202793 doi: 10.3389/fmed.2023.1202793.
8. Lake JC, Victor G, Clare G, et al. Toric intraocular lens versus limbal relaxing incisions for corneal astigmatism after phacoemulsification. *Cochrane Database Syst Rev.* 2019;12(12):CD012801. doi: 10.1002/14651858. CD012801. pub2.
9. Miller AD, Kris MJ, Griffiths AC. Effect of small focal errors on vision. *Optom Vis Sci.* 1997;74(7):521-526.
10. enVista Toric Directions for Use, Bausch & Lomb.
11. Holland EJ. Treating Astigmatism With Torics. In: *Cataract & Refractive Surgery Today Supplement.* 2010 Feb. p. 5-6. Available from: [https://crstoday.com/wp-content/themes/crst/assets/downloads/0210\\_supp.pdf](https://crstoday.com/wp-content/themes/crst/assets/downloads/0210_supp.pdf)
12. enVista Envy Directions for Use, Bausch & Lomb.
13. Clareon PanOptix Directions for Use, Alcon.
14. TECNIS Odyssey Directions for Use, Johnson & Johnson.
15. Novis C. Astigmatism and Toric Intraocular Lenses. *Current Opinion in Ophthalmology* 2000; Vol. 11, Issue 1: 47-50.
16. Bozukova D, Pagnoulle C, Jérôme C. Biomechanical and optical properties of 2 new hydrophobic platforms for intraocular lenses. *J Cataract Refract Surg.* 2013;39(9):1404-1414.
17. Whitman J. Comparative assessment of radial compression forces exerted by various hydrophobic acrylic toric IOLs. *Caribbean Eye.* Cancun, Mexico. 2020.
18. Pantanelli SM, Kansara N, Smits G. Predictability of residual postoperative astigmatism after implantation of a toric intraocular lens using two different calculators. *Clin Ophthalmol.* 2020;14:3627-3634. doi: 10.2147/OPH.S276285.
19. Melles RB, Kane JX, Olsen T, Chang WJ. Update on intraocular lens calculation formulas. *Ophthalmol.* 2019;126(9):1334-1335.
20. Data on file. Blis Inserter.
21. Data on file. INJ100 Inserter.
22. Elachchabi A, Martin P, Goldberg E, et al. Nanoindentation studies on hydrophobic acrylic IOLs to evaluate surface mechanical properties. Paper presented at: XXV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS); September 8-12, 2007; Stockholm, Sweden.
23. enVista Aspire Directions for Use.
24. Pai HV, Pathan A, Kamath YS. A comparison of posterior capsular opacification after implantation of three different hydrophobic square edge intraocular lenses. *Indian J Ophthalmol.* 2019;67(9):1424-1427. doi: 10.4103/ijo.IJO\_S219\_19.
25. Bordewyk AN, et al. Cataract surgery refractive outcomes in long eyes: a comparison of 7 formulas. The Association for Research in Vision and Ophthalmology Annual Meeting; May 1-7, 2021; Virtual.
26. Wiley WF. Rotational stability of aberration neutral hydrophobic toric IOL with enhanced delivery characteristics. Presented at: ASCRS Annual Meeting; April 22-26, 2022; Washington, D.C.

For more information about  
enVista Envy™ & enVista Envy™ Toric  
please visit **[bauschsurgical.com](https://bauschsurgical.com)**

